Pheon Therapeutics, a London, UK-based Antibody Drug Conjugate company developing a pipeline of monotherapies for targets and/or with payloads, raised $68M in Series A funding.
The round was led by Brandon Capital, Forbion and Atlas Venture, with participation from Research Corporation Technologies.
The company intends to use the funds to advance its lead ADC program to clinical proof-of-concept and establish a pipeline of novel ADCs.
Led by CEO Bertrand Damour and CSO Leigh Zawel, Pheon Therapeutics is advancing a pipeline of monotherapies for novel targets and/or with novel payloads based on Antibody Drug Conjugates (ADCs). ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon’s program is an ADC against a novel target that is expressed in solid tumors across a broad range of cancer types.
The company’s board includes Michael Gladstone, Partner at Atlas Venture; Jonathan Tobin, Chair, Partner at Brandon Capital; Rogier Rooswinkel, General Partner at Forbion; and Shaun Kirkpatrick, President Biotechnologies at Research Corporation Technologies (RCT) and Bertrand Damour, CEO of Pheon Therapeutics.
FinSMEs
28/09/2022